An evidence-based approach to the management of pulmonary arterial hypertension.
Coyne
Terrance C
TC
D000959:Antihypertensive Agents / Q000627:therapeutic use; D000077300:Bosentan; D019468:Disease Management; D004347:Drug Interactions; D065128:Endothelin Receptor Antagonists; D019317:Evidence-Based Medicine / Q000379:methods*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000503:physiopathology / Q000628:therapy*; D007555:Isoxazoles / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones; D013876:Thiophenes / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D016138:Walking / Q000502:physiology
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D007555:Isoxazoles; D010879:Piperazines; D011687:Purines; D013449:Sulfonamides; D013450:Sulfones; D013876:Thiophenes; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; C106276:sitaxsentan; D000077300:Bosentan